

# ASX Release

---

## **Rights Issue Closes Significantly Oversubscribed**

- **Renounceable rights offer closes oversubscribed with proceeds of \$6.1m**
- **Additional placement of \$0.7m (total proceeds \$6.8m)**

**PERTH, AUSTRALIA – 31 JULY 2018:** SUDA Pharmaceuticals Ltd (ASX: SUD), a leader in oro-mucosal drug delivery, is pleased to announce that the renounceable rights issue announced on 2 July 2018 closed on 26 July 2018 and has been well supported by the Company's shareholders and new investors (including institutions and sophisticated investors) and closed heavily oversubscribed.

The Company has raised \$6.12m (before costs) and will issue 1,224,141,800 shares and 612,070,900 listed options in accordance with the Prospectus timetable. The new options will be listed under the ASX code SUDOC.

Due to the overwhelming demand, the Company has agreed to place a further 133,675,200 fully paid ordinary shares at \$0.005 and attaching 66,837,600 SUDOC options to raise an additional \$668,376 ("Placement").

The securities will be issued without shareholder approval and using the Company's existing capacity under Listing Rule 7.1. Funds raised from the Placement will be used to supplement working capital.

The Board would like to take the opportunity to thank all our shareholders for their vote of confidence in the future direction of the business. The 2018-19 financial year is set to be a milestone year for the Company and we look forward to your continued support.



**Further information:**  
**STEPHEN CARTER**  
**CHIEF EXECUTIVE OFFICER/MANAGING DIRECTOR**  
**SUDA Pharmaceuticals Ltd**  
Tel: +61 8 6142 5555  
[sjcarter@sudapharma.com](mailto:sjcarter@sudapharma.com)

**NOTES TO EDITORS:**

**About SUDA Pharmaceuticals Ltd**

SUDA Pharmaceuticals Ltd (ASX: SUD) is a drug delivery company focused on oro-mucosal administration, headquartered in Perth, Western Australia. The Company is developing low-risk oral sprays using its OroMist® technology to reformulate existing pharmaceuticals. The many potential benefits of administering drugs through the oral mucosa (i.e.: cheeks, tongue, gums and palate) include ease of use, lower dosage, reduced side effects and faster response time. SUDA's product pipeline includes ZolpiMist™, a first-in-class oral spray of zolpidem for insomnia. ZolpiMist is marketed in the USA and SUDA has rights to the product outside of the US and Canada. ZolpiMist is partnered with Eddingpharm in China and Teva Pharmaceuticals in Latin America. SUDA has submitted a Marketing Authorisation Application to the Australian Therapeutic Goods Administration for ArTiMist®, its novel sublingual malaria treatment for children. In a Phase III trial, ArTiMist was shown to be superior to intravenous quinine. Other products in development include oral sprays for the treatment of migraine headache, chemotherapy-induced nausea and vomiting, erectile dysfunction, PAH, epileptic seizures and pre-procedural anxiety. For more information, visit [www.sudapharma.com](http://www.sudapharma.com)